Brokerages Set Guardant Health, Inc. (NASDAQ:GH) PT at $77.14

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus rating of “Moderate Buy” from the twenty-four research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and twenty-three have given a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $77.1429.

A number of equities research analysts recently commented on GH shares. Mizuho set a $100.00 price target on Guardant Health in a research report on Thursday, October 30th. Stifel Nicolaus set a $73.00 target price on Guardant Health in a report on Thursday, September 25th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a research note on Thursday, September 25th. Evercore ISI lifted their price target on Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, TD Cowen increased their price objective on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, September 25th.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $96.72 on Thursday. Guardant Health has a 52-week low of $28.20 and a 52-week high of $100.22. The business has a fifty day moving average of $67.52 and a two-hundred day moving average of $55.05. The stock has a market cap of $12.19 billion, a PE ratio of -30.13 and a beta of 1.56.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.26). The company had revenue of $265.20 million for the quarter, compared to analysts’ expectations of $235.72 million. The firm’s revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Analysts predict that Guardant Health will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Medina Manuel Hidalgo sold 2,165 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director owned 851 shares in the company, valued at $46,090.16. The trade was a 71.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helmy Eltoukhy sold 300,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at $126,242,015.55. This trade represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 302,691 shares of company stock valued at $17,984,628. 6.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Guardant Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. grew its position in shares of Guardant Health by 6.6% during the 3rd quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company’s stock worth $320,378,000 after buying an additional 317,906 shares during the period. Invesco Ltd. boosted its stake in Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock worth $185,184,000 after acquiring an additional 763,834 shares during the last quarter. Geode Capital Management LLC grew its holdings in Guardant Health by 0.5% during the second quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company’s stock valued at $152,014,000 after purchasing an additional 13,088 shares during the period. ARK Investment Management LLC grew its holdings in Guardant Health by 100.4% during the second quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company’s stock valued at $146,935,000 after purchasing an additional 1,414,381 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Guardant Health by 6.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after purchasing an additional 164,263 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.